Dr. Lancet is an experienced clinician and clinical investigator in the field of AML. He has written, led, conducted, and published many impactful clinical trials in AML, including as lead clinical investigator in the development of CPX-351 (daunorubicin/cytarabine liposome) from inception through the conclusion of the pivotal phase 3 clinical trial culminating in its FDA approval in secondary AML. In addition, he has led and published several AML clinical trials through national organizations such as ASH and CTEP. As the Chair of the Department of Malignant Hematology at Moffitt Cancer Center, Dr. Lancet has experience in leading and coordinating major projects and initiatives within the field of malignant hematology. Dr. Lancet’s clinical practice focuses on the care of primarily older adults with AML and MDS.